U.S. markets close in 4 hours 11 minutes
  • S&P 500

    4,558.35
    +13.45 (+0.30%)
     
  • Dow 30

    35,719.03
    +42.01 (+0.12%)
     
  • Nasdaq

    15,169.26
    +79.06 (+0.52%)
     
  • Russell 2000

    2,311.69
    +20.42 (+0.89%)
     
  • Crude Oil

    84.46
    +0.70 (+0.84%)
     
  • Gold

    1,809.30
    +13.00 (+0.72%)
     
  • Silver

    24.60
    +0.15 (+0.62%)
     
  • EUR/USD

    1.1616
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    1.6290
    -0.0260 (-1.57%)
     
  • GBP/USD

    1.3778
    +0.0019 (+0.14%)
     
  • USD/JPY

    113.6800
    +0.2200 (+0.19%)
     
  • BTC-USD

    63,446.18
    +3,215.43 (+5.34%)
     
  • CMC Crypto 200

    1,512.11
    +1,269.43 (+523.09%)
     
  • FTSE 100

    7,228.93
    +24.38 (+0.34%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2.

  • The chromosomal abnormality is responsible for about 15% to 20% of multiple myeloma cases and is associated with poor patient prognosis.

  • Data were presented at the European Hematology Association virtual congress.

  • Epizyme tested EPZ-719 in mice bearing myeloma tumors with the mutation. The drug safely induced strong tumor growth inhibition of up to 95%.

  • Tumor regressions were observed in mice that got the drug at the top three doses tested.

  • The investigators also reported anti-tumor effects in two mouse models of myeloma without the mutation. The drug produced maximum tumor growth inhibition of 79% in one type and 92% in the other at a high dose.

  • Price Action: EPZM shares are up 2.99% at $8.79 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.